ReviewOncoimmunology2014
Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity.
Review in Oncoimmunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 58 citations in OpenAlex.
- Cascade-targeted delivery platform enhances antigen cross-presentation and STING activation for durable cellular immunity.Bioactive materials · 2025Article
- Reduced Cish expression by siRNA knockdown in Natural Killer cells promotes anti-tumor effects against gastric cancer cell lines.Discover oncology · 2025Article
- A predictive nomogram for short-term outcomes of myasthenia gravis patients treated with low-dose rituximab.CNS neuroscience & therapeutics · 2024Article
- FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study.Frontiers in immunology · 2024Article
- Immunotherapy for HER-2 positive breast cancer.Frontiers in oncology · 2023Review
- ZL-1211 Exhibits Robust Antitumor Activity by Enhancing ADCC and Activating NK Cell-mediated Inflammation in CLDN18.2-High and -Low Expressing Gastric Cancer Models.Cancer research communications · 2022Article
- Characterization of cisplatin-loaded chitosan nanoparticles and rituximab-linked surfaces as target-specific injectable nano-formulations for combating cancer.Scientific reports · 2022Article
- The emerging roles of TRIM21 in coordinating cancer metabolism, immunity and cancer treatment.Frontiers in immunology · 2022Review
- Monoclonal antibody-based therapies for Waldenström's macroglobulinemia.Leukemia research reports · 2022Article
- Review
- B cell heterogeneity, plasticity, and functional diversity in cancer microenvironments.Oncogene · 2021Review
- Antibody-secreting macrophages generated using CpG-free plasmid eliminate tumor cells through antibody-dependent cellular phagocytosis.BMB reports · 2020Article
- A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy.Oncoimmunology · 2020Article
- Colorectal Cancer Immunotherapy: Options and Strategies.Frontiers in immunology · 2020Review
- Review
- Impaired dendritic cell functions in lung cancer: a review of recent advances and future perspectives.Cancer communications (London, England) · 2019Review
- NK-mediated antibody-dependent cell-mediated cytotoxicity in solid tumors: biological evidence and clinical perspectives.Annals of translational medicine · 2019Review
- Non-Genetically Improving the Natural Cytotoxicity of Natural Killer (NK) Cells.Frontiers in immunology · 2019Review
- Bioactive Nanoparticles for Cancer Immunotherapy.International journal of molecular sciences · 2018Review
- Peripheral blood T cell alterations in newly diagnosed diffuse large B cell lymphoma patients and their long-term dynamics upon rituximab-based chemoimmunotherapy.Cancer immunology, immunotherapy : CII · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor antigen (TA)-targeting monoclonal antibody (mAb)-based treatments are considered to be one of the most successful strategies in cancer therapy. Besides targeting TAs and inducing tumor cell death, such antibodies interact with immune cells through Fc-dependent mechanisms to induce adaptive memory immune responses. However, multiple inhibitory/immunosuppressive pathways can be induced by tumor cells to limit the establishment of an efficient antitumor response and consequently a sustained clinical response to TA-targeting mAbs. Here, we provide an overview on how TA-targeting mAbs in combination with conventional cancer therapies and/or inhibitors of key immunosuppressive pathways might represent promising approaches to achieve long-term tumor control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.